• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Patient Preference and Adherence >Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study
【24h】

Patient satisfaction after switching from warfarin to apixaban in patients with nonvalvular atrial fibrillation: AGAIN study

机译：非瓣膜性房颤患者从华法林转为阿哌沙班后的患者满意度：AGAIN研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Purpose: Patients treated with warfarin must adhere to frequent monitoring, dietary restrictions, and complicated dose adjustments. Apixaban, a direct factor Xa inhibitor, is an alternative to warfarin that may reduce patient burdens associated with warfarin therapy. However, there is limited evidence pertaining to patient satisfaction with anticoagulant therapies in Japanese patients. The purpose of this observational study was to investigate changes in patient satisfaction after switching from warfarin to apixaban. Patients and methods: Nonvalvular atrial fibrillation (NVAF) patients who were scheduled to switch anticoagulants from warfarin to apixaban were enrolled and treated with apixaban for 12?weeks. Patient satisfaction was assessed before the change in medication and after 12 weeks of treatment with apixaban using the Anti-Clot Treatment Scale (ACTS), a patient-reported instrument for measuring satisfaction with anticoagulation treatment. The ACTS includes a 12-item burden scale (maximum 60 points) and a 3-item benefit scale (maximum 15 points). Results: Among 732 NVAF patients enrolled, the full analysis set consisted of 697 patients who completed two ACTS assessments (one before the medication change and one 12 weeks after the change). Mean (±standard deviation) patient age was 76.2±9.1 years and mean CHADS2 score was 2.5±1.3. There were no significant changes in ACTS benefit scores. However, ACTS burden scores showed significant improvements at Week 12 compared to baseline (55.6±5.3 at Week 12 and 49.7±8.7 at baseline; P <0.0001). Factors associated with changes in ACTS burden scores from the multiple logistic regression analysis were age ≥70 years (odds ratio [OR]: 1.86; 95% confidence interval [CI]: 1.12–3.10; P =0.0169), baseline ACTS burden score (OR: 0.79; 95% CI: 0.75–0.82; P <0.0001), and use of non-steroidal anti-inflammatory drugs/antiplatelet drugs (OR: 0.60; 95% CI: 0.36–1.00; P =0.0499). Conclusion: Switching from warfarin to apixaban improved patient satisfaction with anticoagulant therapy in Japanese patients with NVAF by reducing burden of treatment.
机译：目的：接受华法令治疗的患者必须坚持经常监测，饮食限制和复杂的剂量调整。阿哌沙班是一种直接的Xa因子抑制剂，是华法林的替代品，可减少与华法林治疗有关的患者负担。但是，在日本患者中，关于患者对抗凝疗法的满意度的证据有限。这项观察性研究的目的是调查从华法林转为阿哌沙班后患者满意度的变化。患者和方法：招募计划将抗凝药从华法林改为阿哌沙班的非瓣膜性心房颤动（NVAF）患者，并接受阿哌沙班治疗12周。在更换药物之前和使用阿哌沙班治疗12周后，使用抗凝治疗量表（ACTS）（一种患者测量抗凝治疗的满意度的仪器）评估患者的满意度。 ACTS包括12个项目的负担量表（最大60分）和3个项目的利益量表（最大15分）。结果：纳入的732例NVAF患者中，完整的分析集由697例患者组成，这些患者完成了两次ACTS评估（一个在更换药物之前，一个在更换药物之后12周）。平均（±标准差）患者年龄为76.2±9.1岁，平均CHADS2评分为2.5±1.3。 ACTS收益评分没有明显变化。然而，与基线相比，ACTS负荷评分在第12周有显着改善（第12周为55.6±5.3，基线为49.7±8.7; P <0.0001）。多元逻辑回归分析与ACTS负荷评分变化相关的因素是年龄≥70岁（优势比[OR]：1.86; 95％置信区间[CI]：1.12-3.10; P = 0.0169），基线ACTS负荷评分（ OR：0.79; 95％CI：0.75-0.82; P <0.0001），并使用非甾体类抗炎药/抗血小板药（OR：0.60; 95％CI：0.36-1.00; P = 0.0499）。结论：通过减少治疗负担，从华法林转为阿哌沙班可以提高日本NVAF患者抗凝治疗的满意度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号